KION GROUP AG (FRA:KGX)

Inozyme Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	619.5	787	311.8	318.1	483	314.4
Cash & Short-Term Investments	619.5	787	311.8	318.1	483	314.4
Cash Growth	128.09%	152.41%	-1.98%	-34.14%	53.63%	48.86%
Accounts Receivable	2,617	2,698	2,772	2,716	2,323	1,741
Other Receivables	76.6	187.4	152.2	201.3	158.2	120.6
Receivables	2,694	2,885	2,924	2,917	2,482	1,862
Inventory	1,766	1,749	1,817	1,805	1,632	1,101
Other Current Assets	348.5	148.5	170.6	146.8	101.2	112.4
Total Current Assets	5,428	5,569	5,223	5,187	4,698	3,389
Property, Plant & Equipment	4,373	4,204	3,754	3,412	3,260	3,080
Long-Term Investments	108.7	240.2	199.5	175.1	152.1	158.9
Goodwill	3,435	3,648	3,558	3,619	3,545	3,408
Other Intangible Assets	2,064	2,167	2,107	2,162	2,166	2,152
Long-Term Accounts Receivable	2,225	2,089	1,702	1,371	1,319	1,199
Long-Term Deferred Tax Assets	494.5	489.3	443.2	300.8	449.3	494.9
Other Long-Term Assets	303	398.7	401.6	373.1	261.9	174.1
Total Assets	18,431	18,805	17,388	16,599	15,851	14,056
Accounts Payable	1,228	1,160	1,194	1,124	1,444	910.5
Accrued Expenses	-	714	706.5	599.7	612.5	498.4
Short-Term Debt	-	-	20	305	-	-
Current Portion of Long-Term Debt	1,661	1,316	742	783	506.5	511.9
Current Portion of Leases	497.3	942.3	824.3	747.1	1,206	850.7
Current Income Taxes Payable	27.5	75	89.3	42.4	51.4	44.9
Current Unearned Revenue	688.8	920.7	915.4	975.4	1,064	781
Other Current Liabilities	1,474	381.9	460.3	373.9	220.6	220.9
Total Current Liabilities	5,576	5,510	4,952	4,951	5,105	3,818
Long-Term Debt	3,504	2,529	2,615	2,526	1,921	2,297
Long-Term Leases	1,979	2,905	2,433	1,971	1,520	1,307
Long-Term Unearned Revenue	-	200.6	173.4	180.6	184.7	228.2
Long-Term Deferred Tax Liabilities	420.3	446.7	448.9	492.8	523.5	511.1
Other Long-Term Liabilities	392.2	259.4	218	157.6	162.2	173.1
Total Liabilities	12,545	12,598	11,616	10,992	10,682	9,785
Common Stock	131.1	131.1	131.1	131.1	131.1	131.1
Retained Earnings	2,075	2,136	1,867	1,601	1,699	1,185
Comprehensive Income & Other	3,662	3,923	3,768	3,877	3,347	2,968
Total Common Equity	5,868	6,189	5,767	5,609	5,177	4,284
Minority Interest	18.4	17.7	5.9	-0.9	-8.3	-13.1
Shareholders' Equity	5,886	6,207	5,773	5,608	5,169	4,271
Total Liabilities & Equity	18,431	18,805	17,388	16,599	15,851	14,056
Total Debt	7,640	7,692	6,634	6,332	5,154	4,967
Net Cash (Debt)	-7,021	-6,905	-6,322	-6,014	-4,671	-4,652
Net Cash Per Share	-53.55	-52.67	-48.23	-45.87	-35.63	-39.13
Filing Date Shares Outstanding	131.12	131.12	131.12	131.12	131.1	131.09
Total Common Shares Outstanding	131.12	131.12	131.12	131.12	131.1	131.09
Working Capital	-147.8	58.8	271.5	235.9	-407.4	-428.9
Book Value Per Share	44.75	47.20	43.98	42.77	39.49	32.68
Tangible Book Value	368.4	374.5	101.9	-172.9	-533.6	-1,276
Tangible Book Value Per Share	2.81	2.86	0.78	-1.32	-4.07	-9.73
Land	-	931.1	895.6	872.6	831.7	781.9
Machinery	-	2,914	2,920	2,640	2,363	2,186
Order Backlog	-	4,635	6,045	7,078	6,659	4,441

Source: S&P Global Market Intelligence. Standard template. Financial Sources.